Patients with OSA show a rapid decrease in serum and plasma BDNF levels during initiation of the treatment [with positive airway pressure (PAP)-device], likely reflecting enhanced neuronal demand for BDNF in this condition41. The gene discussed is BDNF; the disease is obstructive sleep apnea syndrome.